1-9 of 9
Melinda G. Hollingshead
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers

Deborah F. Wilsker, Allison M. Barrett, Angie B. Dull, Scott M. Lawrence, Melinda G. Hollingshead, Alice Chen, Shivaani Kummar, Ralph E. Parchment, James H. Doroshow, Robert J. Kinders
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (10): 3084–3095.
https://doi.org/10.1158/1078-0432.CCR-18-2523
Published: 15 May 2019
View article titled, Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers
Open the PDF for Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Apurva K. Srivastava, Melinda G. Hollingshead, Jennifer Weiner, Tony Navas, Yvonne A. Evrard, Sonny A. Khin, Jiuping Jay Ji, Yiping Zhang, Suzanne Borgel, Thomas D. Pfister, Robert J. Kinders, Donald P. Bottaro, W. Marston Linehan, Joseph E. Tomaszewski, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (14): 3683–3694.
https://doi.org/10.1158/1078-0432.CCR-15-2323
Published: 14 July 2016
View article titled, Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Open the PDF for Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays in another window
Includes: Supplementary data
Journal Articles

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

Apurva K. Srivastava, Soumya Jaganathan, Laurie Stephen, Melinda G. Hollingshead, Adam Layhee, Eric Damour, Jeevan Prasaad Govindharajulu, Jennifer Donohue, Dominic Esposito, James P. Mapes, Robert J. Kinders, Naoko Takebe, Joseph E. Tomaszewski, Shivaani Kummar, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 1000–1010.
https://doi.org/10.1158/1078-0432.CCR-14-3156
Published: 14 February 2016
View article titled, Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Open the PDF for Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use in another window
Includes: Supplementary data
Journal Articles

Proteomic Analysis Identifies Oxidative Stress Induction by Adaphostin

Luke H. Stockwin, Maja A. Bumke, Sherry X. Yu, Simon P. Webb, Jack R. Collins, Melinda G. Hollingshead, Dianne L. Newton
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3667–3681.
https://doi.org/10.1158/1078-0432.CCR-07-0025
Published: 15 June 2007
View article titled, Proteomic Analysis Identifies Oxidative Stress Induction by Adaphostin
Open the PDF for Proteomic Analysis Identifies Oxidative Stress Induction by Adaphostin in another window
Journal Articles

Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Lyuba Varticovski, Melinda G. Hollingshead, Ana I. Robles, Xiaolin Wu, James Cherry, David J. Munroe, Luanne Lukes, Miriam R. Anver, John P. Carter, Suzanne D. Borgel, Howard Stotler, Carrie A. Bonomi, Nomelí P. Nunez, Stephen D. Hursting, Wenhui Qiao, Chuxia X. Deng, Jeff E. Green, Kent W. Hunter, Glenn Merlino, Patricia S. Steeg, Lalage M. Wakefield, J. Carl Barrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2168–2177.
https://doi.org/10.1158/1078-0432.CCR-06-0918
Published: 02 April 2007
View article titled, Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models
Open the PDF for Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone)

Christopher A. Barker, William E. Burgan, Donna J. Carter, David Cerna, David Gius, Melinda G. Hollingshead, Kevin Camphausen, Philip J. Tofilon
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2912–2918.
https://doi.org/10.1158/1078-0432.CCR-05-2860
Published: 04 May 2006
View article titled, <em>In vitro</em> and <em>In vivo</em> Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone)
Open the PDF for <em>In vitro</em> and <em>In vivo</em> Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone) in another window
Journal Articles

Enhancement of In vitro and In vivo Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine

Hideaki Dote, David Cerna, William E. Burgan, Donna J. Carter, Michael A. Cerra, Melinda G. Hollingshead, Kevin Camphausen, Philip J. Tofilon
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4571–4579.
https://doi.org/10.1158/1078-0432.CCR-05-0050
Published: 15 June 2005
View article titled, Enhancement of <em>In vitro</em> and <em>In vivo</em> Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine
Open the PDF for Enhancement of <em>In vitro</em> and <em>In vivo</em> Tumor Cell Radiosensitivity by the DNA Methylation Inhibitor Zebularine in another window
Journal Articles

Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin

Elizabeth E. A. Bull, Hideaki Dote, Kristin J. Brady, William E. Burgan, Donna J. Carter, Michael A. Cerra, Kelli A. Oswald, Melinda G. Hollingshead, Kevin Camphausen, Philip J. Tofilon
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (23): 8077–8084.
https://doi.org/10.1158/1078-0432.CCR-04-1212
Published: 07 December 2004
View article titled, Enhanced Tumor Cell Radiosensitivity and Abrogation of G<sub>2</sub> and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin
Open the PDF for Enhanced Tumor Cell Radiosensitivity and Abrogation of G<sub>2</sub> and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin in another window
Journal Articles

Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3646–3657.
Published: 01 December 2002
View article titled, Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle>
Open the PDF for Testing of New Agents in Childhood Cancer Preclinical Models: <subtitle>Meeting Summary</subtitle> in another window